Related Experiment Videos
[Iatrogenic mycoses with deep visceral localization caused by opportunistic fungi]
Abstract:
The new therapeutic methods based on antibiotics, corticosteroids and immunosuppressors and the new medicosurgical techniques (catheters, monitoring in intensive-care units, open-heart surgery) modify the host, favorise the adaptation and introduction f endogenous and exogenous yeast-like fungi and thus create a new pathology characterized by deep visceral or septicemic infections due to yeasts belonging to the genera Candida, Torulopsis, Cryptococcus, Trichosporon, Rhodotorula, and Saccharomyces. The pathological aspects are analyzed and therapy is suggested in the light of new findings on polyenes (nystatine, amphotericine B), 5-fluorocytosine, imidazole, derivatives (miconazole, econazole) considering their association in function of synergy or antagonism possibilities.
Insights
New medical treatments and surgical techniques increase the risk of deep fungal infections. This study analyzes these yeast infections and suggests therapies, including polyenes and azoles.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Medicine
Background:
- Modern therapeutics like antibiotics, corticosteroids, and immunosuppressors alter host defenses.
- Advanced medical interventions, including catheter use and intensive care, facilitate fungal adaptation and infection.
- This creates a new spectrum of deep visceral and septicemic infections caused by yeast-like fungi.
Purpose of the Study:
- To analyze the pathological aspects of emerging yeast-like fungal infections.
- To suggest therapeutic strategies for these infections based on current antifungal research.
- To evaluate the potential synergistic or antagonistic interactions of antifungal agents.
Main Methods:
- Review of clinical cases and pathological findings related to yeast infections.
- Analysis of the efficacy and application of various antifungal agents.
- Consideration of drug interactions for combination therapy.
Main Results:
- Identification of key yeast genera (Candida, Torulopsis, Cryptococcus, etc.) responsible for deep infections.
- Evaluation of antifungal agents including polyenes (amphotericin B), 5-fluorocytosine, and imidazoles (miconazole, econazole).
- Exploration of therapeutic associations based on potential synergy or antagonism.
Conclusions:
- Medical advancements have inadvertently led to increased risks of severe yeast-like fungal infections.
- Effective management requires understanding the specific pathogens and employing targeted antifungal therapies.
- Combination antifungal therapy may offer improved outcomes but requires careful consideration of drug interactions.